TRUP Maintained by Stifel -- Price Target Raised to $29.00
Stifel has maintained a "Hold" rating for Trupanion (TRUP) but raised its price target from $28.00 to $29.00. GuruFocus indicates TRUP is 22.7% undervalued with a GF Value of $40.26 and a strong GF Score of 79/100, though insider selling has been noted.
Stifel raises Trupanion stock price target on Pets Best exit
Stifel increased its price target for Trupanion (NASDAQ:TRUP) to $29.00 from $28.00 while maintaining a Hold rating, following Trupanion's announcement to end its partnership with Pets Best by Q3 2028. Pets Best represented a significant portion of Trupanion's 2025 revenue, and the model projects a gradual decline in this segment. Despite the adjustment, the company is expected to remain profitable, as supported by its recent Q2 2026 earnings which surpassed expectations.
Trupanion, Inc. (TRUP) PT Raised to $29 at Stifel as Pets Best Rolls Off Business
Stifel analyst Jonathan Block increased the price target for Trupanion, Inc. (TRUP) to $29.00 from $28.00, while maintaining a Hold rating. This adjustment follows the agreement between Trupanion and Pets Best to conclude their relationship after Q3 2028, which is expected to result in a material revenue headwind as Pets Best accounted for 30% of Trupanion's total 2025 revenue. Despite the revenue loss, the adjusted operating income from the "Other" business segment (which included Pets Best) was only 1-2% of segment revenue, and the analyst's model anticipates a gradual decline to zero by the end of 2033, with a focus on winding down fixed costs.
Is Trupanion (TRUP) Undervalued Following Its New Pet Care Partnerships?
Trupanion (TRUP) has garnered attention due to new partnerships aimed at improving pet care through insurance education and easier claims, leading to recent share price increases. While a popular narrative suggests the stock is 17.9% undervalued with a fair value of $37.25, another view points to its high P/E ratio of 57.8x compared to industry averages, indicating investors are already paying a significant premium for its earnings. The article advises investors to further analyze the data given the split sentiment between valuation concerns and future optimism.
GSA Capital Partners LLP Purchases Shares of 56,264 Trupanion, Inc. $TRUP
GSA Capital Partners LLP recently acquired 56,264 shares of Trupanion, Inc. for approximately $1.39 million, establishing a new position in the company. This comes as other institutional investors have increased their holdings, despite some insider selling. Trupanion surpassed quarterly earnings expectations with adjusted EPS of $0.16 and revenue of $392.93 million, leading analysts to maintain a "Moderate Buy" rating with a target price of $41.60.
Trupanion Inc. Earnings Call Highlights Growth Momentum
Trupanion Inc. reported strong Q2 earnings, with total revenue up 11% year-over-year and adjusted operating income climbing 24%. The company highlighted accelerating pet enrollment, improved unit economics, and significant free cash flow generation, demonstrating confidence in its ability to navigate industry challenges like veterinary inflation. Despite a decrease in net income attributed to a non-recurring gain last year and a transition risk with partner Pets Best, Trupanion provided optimistic 2026 guidance, projecting continued double-digit growth.
Trupanion (TRUP) Is Up 13.4% After New Vet Partnerships and Q2 Results - Has The Bull Case Changed?
Trupanion (TRUP) stock rose 13.4% following its Q2 2026 results, which included updated revenue guidance and new partnerships with Digitail and Home To Home. These collaborations aim to integrate Trupanion's VetDirect Pay and Exam Day coverage into veterinary workflows and pet rehoming processes, reinforcing its margin-focused, subscription-driven growth strategy. While analysts forecast significant revenue and earnings growth by 2029, a $37.25 fair value suggests a 22% upside, though competitive pressures and rising veterinary costs pose potential risks.
Trupanion (TRUP) Is Up 13.4% After New Vet Partnerships and Q2 Results - Has The Bull Case Changed?
Trupanion (TRUP) saw a 13.4% stock increase following its Q2 2026 results, which reported net income of US$6.83 million and updated revenue guidance. The company also announced new partnerships with veterinary software provider Digitail and rehoming platform Home To Home, aiming to integrate its services deeper into the pet care journey. These strategic moves are expected to reinforce Trupanion's subscription-driven investment narrative by improving pet acquisition quality and potentially claim efficiency, supporting its margin-focused growth strategy amidst ongoing market competition.
Renaissance Technologies LLC Has $999,000 Stake in Trupanion, Inc. $TRUP
Renaissance Technologies LLC significantly increased its stake in Trupanion, Inc. by 550% in the first quarter, now holding 39,000 shares valued at approximately $999,000. Trupanion received a "Moderate Buy" consensus rating from analysts with an average price target of $41.60, after reporting strong quarterly earnings of $0.16 EPS against estimates of $0.11, and an 11.1% increase in revenue year-over-year. Despite insider stock sales by the CFO and EVP, institutional investors generally show increased interest in the pet medical insurance provider.
Trupanion CEO Margaret Tooth sells $28,410 in company stock
Trupanion CEO Margaret Tooth sold 978 shares of company stock worth $28,410 on August 11, 2026, as part of a pre-scheduled diversification plan. Following the sale, she still holds 175,401 shares. Despite the insider sale and a 39% decline over the past year, the stock recently gained 10% and is considered undervalued by InvestingPro analysts, with the company also exceeding Q2 2026 profit expectations.
5 Must-Read Analyst Questions From Trupanion’s Q2 Earnings Call
Trupanion reported better-than-expected Q2 2026 results, driven by increased pet enrollments and improved web conversion. Revenue reached $392.9 million, exceeding analyst estimates, and GAAP EPS hit $0.16. Key analyst questions focused on veterinary inflation, credit facility usage, the share repurchase program, and the impact of new product rollouts, with management providing insights into these strategic areas.
Trupanion CEO Margaret Tooth sells $28,410 in company stock By Investing.com
Trupanion CEO Margaret Tooth sold 978 shares of company stock for $28,410 on August 11, 2026, as part of a pre-scheduled diversification plan. Despite the stock trading 39% down over the past year, InvestingPro analysis suggests it is undervalued with a PEG ratio of 0.5. The sale follows a strong Q2 2026 earnings report where Trupanion exceeded profit expectations and saw an 11% revenue increase.
Margaret Tooth Sells 978 Shares of Trupanion (NASDAQ:TRUP) Stock
Trupanion CEO Margaret Tooth recently sold 978 shares of the company's stock for a total of $28,410.90 under a pre-arranged Rule 10b5-1 plan. Following the transaction, her ownership stands at 175,401 shares. The company's stock traded up 2.2% to $31.00, and Trupanion reported strong quarterly earnings, beating analyst expectations with an EPS of $0.16 and revenue of $392.93 million.
Trupanion Partners with Home To Home® to Help More Pets Transition Directly from One Loving Home to Another
Trupanion, a leading pet insurer, has announced a partnership with Home To Home®, a direct pet rehoming platform. This collaboration aims to provide new pet families with educational resources, guidance on veterinary expenses, and access to Trupanion's Exam Day Offer, which offers immediate comprehensive coverage. The partnership seeks to support pets transitioning to new homes while also alleviating pressure on animal shelters.
Trupanion Partners with Home To Home® to Help More Pets Transition Directly from One Loving Home to Another
Trupanion, a leading pet insurer, has announced a new partnership with Home To Home®, a direct pet rehoming platform. This collaboration aims to support pets and new families by providing educational resources on veterinary expenses and offering an exclusive Exam Day Offer for immediate comprehensive coverage. The partnership helps ease pet transitions into new homes while assisting shelters by reducing owner surrenders.
Zacks Industry Outlook Highlights Aflac, Globe Life, Trupanion and Employers Holdings
The Zacks Accident and Health Insurance industry is expected to benefit from increased underwriting exposure, with Aflac, Globe Life, Trupanion, and Employers Holdings poised for growth due to rising demand for group insurance. However, the industry faces challenges from persistent medical inflation and pricing pressures, despite advancements in technology like AI and improved claims frequency. The industry currently holds a Zacks Industry Rank #214, indicating bleak near-term prospects despite individual company advancements.
Trupanion (NASDAQ: TRUP) investor files to sell 978 common shares
A Trupanion (NASDAQ: TRUP) shareholder, Margaret R. Tooth, has filed an intention to sell 978 common shares through Morgan Stanley Smith Barney LLC Executive Financial Services. The planned sale, valued at $28,410.90, is scheduled for August 11, 2026, on NASDAQ. This disclosure also notes a previous sale of 491 shares on May 25, 2026, and details restricted stock awards from 2021 and 2022.
First Trust Advisors LP Sells 40,511 Shares of Trupanion, Inc. $TRUP
First Trust Advisors LP significantly reduced its stake in Trupanion, Inc. (NASDAQ:TRUP) by 55% in the first quarter, selling 40,511 shares and retaining 33,122 shares worth approximately $848,000. Despite this, other institutions increased their positions, and Trupanion reported stronger-than-expected quarterly earnings and revenue. Analysts maintain a "Moderate Buy" rating for TRUP, though company insiders have recently sold a notable amount of shares.
Trupanion Enhances Free Veterinary Education Course to Help Hospital Teams Navigate Cost-of-Care Conversations
Trupanion has enhanced its free, on-demand educational course, Trupanion Certification, to help veterinary teams navigate cost-of-care conversations with pet parents. The course aims to equip veterinary professionals with the skills to proactively discuss financial options before emergencies, thereby reducing financial barriers to pet care. Over 33,800 veterinary professionals from more than 5,289 hospitals have already completed the course, which has been praised for improving client communication, operational efficiency, and pet health outcomes.
Trupanion Enhances Free Veterinary Education Course to Help Hospital Teams Navigate Cost-of-Care Conversations
Trupanion has enhanced its free, on-demand educational course, Trupanion Certification, to help veterinary teams confidently discuss the cost of care with pet parents before emergencies arise. This updated course provides role-based learning, interactive scenarios, and practical guidance on financial preparedness and the value of pet medical insurance. Since its launch in 2023, the program has been adopted by over 33,800 veterinary professionals from more than 5,289 hospitals, aiming to reduce financial barriers to pet care and improve client-veterinary communication.
Trupanion Enhances Free Veterinary Education Course to Help Hospital Teams Navigate Cost-of-Care Conversations
Trupanion (NASDAQ:TRUP) has announced significant enhancements to its free, on-demand Trupanion Certification course, designed to help veterinary professionals discuss pet care costs with owners before emergencies arise. The updated course, which has already been completed by over 33,800 professionals, now features role-based learning, interactive scenarios, and expanded education on pet medical insurance and direct payment models. This initiative aims to reduce financial barriers to pet care and improve communication between veterinary teams and pet parents.
Trupanion, Inc. (NASDAQ:TRUP) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Trupanion, Inc. (NASDAQ:TRUP) has received a "Moderate Buy" consensus recommendation from analysts, with an average 12-month price target of $41.60. The company recently surpassed quarterly expectations with adjusted EPS of $0.16 and revenue of $392.93 million, though its stock opened significantly below its 52-week high. Insider selling of 17,807 shares occurred in the last quarter, valued at approximately $394,452.
Trupanion Inc (TRUP-Q) Stock Price and News
This article provides stock information and recent news for Trupanion Inc (TRUP-Q), a pet medical insurance provider. It includes real-time stock data, a list of recent news articles related to the company's Q2 2026 earnings, product enhancements, and analyst ratings, along with company profile details.
Trupanion (TRUP) Could Be 28% Undervalued As Earnings Beat And Guidance Improves
Trupanion (TRUP) is considered potentially 28% undervalued after reporting strong Q2 2026 earnings, improved guidance, and a new integration agreement with Digitail. While the stock has seen a significant year-to-date decline, recent momentum and a narrative suggesting a fair value of $37.25 indicate a potential upside. However, its current P/E ratio of 51x is significantly higher than industry averages, posing a valuation risk.
Why Trupanion (TRUP) Is Up 10.2% After Mixed Q2 Results, New Guidance, and Digitail Deal
Trupanion (TRUP) shares rose 10.2% after reporting mixed Q2 2026 results, providing updated guidance, and announcing an integration with Digitail. While net income was lower year-over-year, first-half profitability was stronger, and the company projects continued double-digit subscription growth with expected total revenue between US$1.58–US$1.60 billion. An extraordinary US$44 million dividend and a US$100 million share buyback authorization were also announced, alongside the Digitail integration which aims to embed Trupanion's tools into veterinary clinic workflows.
Trupanion (TRUP) Is Up 10.2% After Raising 2026 Revenue Outlook and Authorizing Share Buyback - What's Changed
Trupanion (TRUP) reported strong Q2 2026 results, exceeding revenue and earnings expectations, and raising its full-year 2026 revenue guidance to between US$1.58 billion and US$1.60 billion. The company also announced a US$100 million share repurchase program and a new integration with veterinary software provider Digitail. These developments have positively impacted investor sentiment, with the stock up 10.2%, but its valuation remains a point of debate among analysts.
Dimensional Fund Advisors LP Boosts Stock Holdings in Trupanion, Inc. $TRUP
Dimensional Fund Advisors LP increased its holdings in Trupanion, Inc. (NASDAQ:TRUP) by 15.7% in the first quarter, now owning 702,086 shares valued at $17.98 million. Several other institutional investors also raised their stakes in the company, despite some insider selling. Trupanion reported strong quarterly earnings, exceeding estimates, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $41.60.
Should You Buy, Sell or Hold Trupanion Stock Post Q2 Earnings?
Trupanion Inc. (TRUP) reported strong second-quarter 2026 results, with revenues beating estimates and adjusted EBITDA increasing. Despite this, the article suggests a "wait-and-see" approach for the stock due to its premium valuation, mixed analyst sentiment, and narrowed guidance, even as it operates in a growing pet insurance market. The company benefits from high customer retention, recurring subscription revenues, and a proprietary technology platform, with plans for international expansion and product diversification.
Trupanion (TRUP) Stock Rallies As Cash Flow Strength Reframes The Story
Trupanion (TRUP) stock surged 15% after its Q2 2026 earnings report, which highlighted significant improvements in cash flow and operating discipline, shifting investor focus from growth to profit quality. Subscription adjusted operating income rose, pushing margins to 15.0%, and free cash flow reached US$82.2 million over the past four quarters. Despite a drop in net income and EPS, the company demonstrated stronger unit economics with increased lifetime value per pet and higher retention rates, challenging previous bearish concerns about acquisition costs and pricing impact on loyalty.
Earnings Flash (TRUP) Trupanion, Inc. Reports Q2 Revenue $392.9M, vs. FactSet Est of $389.7M
Trupanion, Inc. (TRUP) announced its Q2 2026 revenue reached $392.9 million, surpassing the FactSet estimate of $389.7 million. The company's stock shows a 5-day change of +15.46% and a year-to-date change of -24.65%, with an average target price of $37.25 from analysts. Trupanion operates as a medical insurance provider for pets in the US, Canada, and parts of Europe, offering subscription-based products and underwriting for third parties.
Trupanion, Inc. 2Q 2026: Revenue $392.9M, EPS $0.16— 10-Q Summary
Trupanion, Inc. reported its second-quarter 2026 results, showing a revenue increase of 11% year-over-year to $392.9M, primarily driven by subscription revenue growth. However, the company experienced a decline in net income to $6.83M and diluted EPS to $0.16 compared to the previous year. Key business highlights include increased marketing spend for pet acquisition, strong veterinary referrals, improved operational efficiency, and ongoing market expansion in Europe and Canada.
Trupanion Inc (TRUP) (Q2 2026) Earnings Call Highlights: Strong Growth and Strategic Capital ...
Trupanion Inc. (TRUP) reported strong Q2 2026 financial results with a 24% increase in subscription adjusted operating income and accelerated net pet growth. The company announced a $100 million share repurchase program and is expanding deductible and coinsurance options to improve accessibility. Despite positive results, veterinary inflation and increased pet acquisition costs remain challenges.
Trupanion (Nasdaq: TRUP) lifts pet insurance revenue 12% in 1H 2026
Trupanion, Inc. (Nasdaq: TRUP) reported a 12% increase in total revenue for the first half of 2026, reaching $776.9 million, driven by strong growth in its subscription business segment. The company's Q2 2026 revenue also grew by 11% year-over-year to $392.9 million, while net income for the first half was $11.7 million. Trupanion announced a new share repurchase program authorizing up to $100.0 million of common stock, though no repurchases were made in the first half of 2026.
TRUPANION ($TRUP) Releases Q2 2026 Earnings, Stock Rises
TRUPANION ($TRUP) released its Q2 2026 earnings, reporting $0.16 per share, which beat estimates, and revenue of $392,930,000, which missed estimates. Following the announcement, the stock price rose by 2.91%. The article also details recent insider trading activity, primarily sales, and hedge fund movements, with more institutions decreasing than increasing their positions.
Trupanion (Nasdaq: TRUP) lifts Q2 revenue 11% and adds $100M repurchase plan
Trupanion reported its Q2 2026 financial results, showing an 11% increase in total revenue to $392.9 million, driven by a 14% rise in subscription business revenue. Despite a 2% decrease in total enrolled pets, subscription pets grew by 5%. The company also announced a new share repurchase program of up to $100 million and approval for a $44 million extraordinary dividend from its insurance subsidiary, while GAAP net income declined to $6.8 million from $9.4 million a year ago.
Trupanion Reports Second Quarter 2026 Results
Trupanion, a leading provider of medical insurance for pets, announced its second quarter 2026 financial results, highlighting an 11% increase in total revenue to $392.9 million compared to Q2 2025. The company reported a net income of $6.8 million and authorized a share repurchase program of up to $100 million, alongside an extraordinary dividend payment of $44 million from its subsidiary. These results underscore Trupanion's focus on growing margin, improving new enrollment economics, and disciplined capital allocation to create shareholder value.
Trupanion Reports Second Quarter 2026 Results
Trupanion, Inc. announced its financial results for the second quarter of 2026, reporting an 11% increase in total revenue to $392.9 million and a net income of $6.8 million. The company also authorized a share repurchase program for up to $100.0 million of its common stock and declared an extraordinary dividend of $44 million. These results highlight Trupanion's continued focus on growing margin, improving new enrollment economics, and disciplined capital allocation.
Trupanion (TRUP) Q2 Earnings and Revenues Beat Estimates
Trupanion (TRUP) reported Q2 earnings of $0.16 per share, surpassing the Zacks Consensus Estimate of $0.11, and revenues of $392.93 million, beating estimates by 0.84%. Despite the strong performance, Trupanion's stock has declined by 34% year-to-date, while the S&P 500 gained 13%. The company holds a Zacks Rank #2 (Buy) based on favorable earnings estimate revisions.
Trupanion faces earnings test as market share slide continues
Trupanion Inc. is set to report its second-quarter earnings, with analysts expecting 11 cents a share on $389.7 million in revenue. The key focus for investors will be whether the pet insurer can stabilize its market share, which has declined for eight consecutive years, and the details of its strategic pivot to broaden product offerings. Despite a "buy" rating from Wall Street and a significant implied upside, concerns remain about declining market share and the impact of rising premiums on new pet additions.
Trupanion Inc earnings beat by $0.05, revenue topped estimates
Trupanion Inc (NASDAQ: TRUP) reported strong second-quarter results, beating analyst estimates for both earnings per share (EPS) and revenue. The company posted an EPS of $0.16, exceeding the $0.11 estimate, and revenue reached $392.93 million against an estimated $389.72 million. Despite this positive earnings report, Trupanion's stock has seen significant declines over the past 3 and 12 months, though its financial health is currently rated as "good performance" by InvestingPro.
Trupanion (TRUP) Faces A 38% Undervalued View, Is The Premium P E Too High?
Trupanion (TRUP) is seen by some as 38% undervalued, with a fair value of $39.75 compared to its recent share price of $24.65, despite its stock being down significantly year-to-date. This valuation is based on assumptions about growth, margins, and improved customer retention due to moderated veterinary care inflation. However, its high P/E ratio of 41.7x, much higher than industry averages, raises questions about whether the market will sustain such a premium, potentially limiting upside or leading to a re-rating.
Less Paperwork. More Pets. The Long-Awaited Trupanion and Digitail Integration Is Here
Trupanion and Digitail have integrated their platforms to streamline operations for veterinary hospitals. This partnership allows real-time claim submissions and payments through Trupanion's VetDirect Pay™ technology directly within the Digitail system, reducing administrative burdens and enabling veterinary teams to focus more on pet care. The integration aims to expand access to care, encourage compliance, and enhance client relationships by simplifying the financial aspects of veterinary services.
Pet care checkout gains one-click claims inside clinic software
Trupanion and Digitail have integrated their platforms to streamline veterinary clinic operations. This new integration allows veterinary teams to submit insurance claims with one click and receive real-time payments directly within Digitail's practice management software, reducing administrative burden and speeding up the checkout process. The collaboration aims to enhance client relationships, encourage care compliance, and improve pet health outcomes by making insurance processes more efficient for over 11,000 North American veterinary hospitals.
Trupanion (TRUP) Reports Q2: Everything You Need To Know Ahead Of Earnings
Trupanion (TRUP), a pet insurance provider, is set to report its Q2 earnings this Wednesday after the bell. The company previously exceeded revenue expectations last quarter with $384 million, a 12.3% year-on-year increase. Analysts anticipate a 10.2% year-on-year revenue growth for the upcoming quarter, with an average analyst price target of $37.25 against the current share price of $24.92.
Trupanion COO John Gallagher sells $10,809 in company stock By Investing.com
Trupanion COO John Gallagher sold 431 shares of company stock for $10,809 on July 28, 2026, under a pre-arranged Rule 10b5-1 trading plan for financial diversification. This transaction occurred while Trupanion's stock trades at $24.48, down 34% year-to-date, though InvestingPro analysis suggests it is undervalued. The company recently exceeded Q1 2026 earnings expectations but faces concerns regarding its product strategy and declining North American market share.
Form 4 Trupanion Inc For: 30 July By Investing.com
This article announces the filing of a Form 4 for Trupanion Inc. on July 30. It is a brief report from Investing.com, providing basic information about the financial filing.
Trupanion COO John Gallagher sells $10,809 in company stock
Trupanion COO John Gallagher sold 431 shares of company stock for $10,809 on July 28, 2026, as part of a pre-arranged diversification plan. The stock is currently down 34% year-to-date but is considered undervalued according to InvestingPro. This sale follows the company's better-than-expected Q1 2026 earnings, though analysts have adjusted price targets due to product strategy concerns and declining market share.
Form 4 Trupanion Inc For: 30 July By Investing.com
This article is a brief financial filing notification from Investing.com, indicating the release of a Form 4 for Trupanion Inc. (TRUP) on July 30. It provides no additional details beyond the filing announcement itself.
Form 4 Trupanion Inc For: 30 July By Investing.com
This article reports on a Form 4 filing by Trupanion Inc. for July 30. It includes the company's stock symbol TRUP and its current performance. The content is primarily a brief note from Investing.com about this financial filing.
Trupanion COO John Gallagher sells $10,809 in company stock
Trupanion COO John Gallagher sold 431 shares of company stock worth $10,809 on July 28, 2026, under a pre-arranged Rule 10b5-1 trading plan for financial diversification. This transaction leaves him with 32,203 shares as the stock currently trades at $24.48, down 34% year-to-date, though InvestingPro analysis suggests it may be undervalued. The sale follows recent positive Q1 2026 earnings for Trupanion, which surpassed revenue and EPS expectations, despite analyst concerns over product strategy and declining North American market share.
